DK1399744T3 - EPF-receptorassays, forbindelser og terapeutiske præparater - Google Patents

EPF-receptorassays, forbindelser og terapeutiske præparater

Info

Publication number
DK1399744T3
DK1399744T3 DK02745422T DK02745422T DK1399744T3 DK 1399744 T3 DK1399744 T3 DK 1399744T3 DK 02745422 T DK02745422 T DK 02745422T DK 02745422 T DK02745422 T DK 02745422T DK 1399744 T3 DK1399744 T3 DK 1399744T3
Authority
DK
Denmark
Prior art keywords
epf
assays
compounds
test compound
receptor assays
Prior art date
Application number
DK02745422T
Other languages
English (en)
Inventor
Arjan Buist
Eckhard Bender
Tom Julia Leon Meeusen
Elke Jenny Henriette Clynen
Liliane Amelie Henrica Schoofs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1399744T3 publication Critical patent/DK1399744T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/36Gynecology or obstetrics
    • G01N2800/368Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
DK02745422T 2001-06-27 2002-06-26 EPF-receptorassays, forbindelser og terapeutiske præparater DK1399744T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202474 2001-06-27
PCT/EP2002/007263 WO2003005036A2 (en) 2001-06-27 2002-06-26 Epf receptor assays, compounds and therapeutic compositions

Publications (1)

Publication Number Publication Date
DK1399744T3 true DK1399744T3 (da) 2008-09-22

Family

ID=8180549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745422T DK1399744T3 (da) 2001-06-27 2002-06-26 EPF-receptorassays, forbindelser og terapeutiske præparater

Country Status (17)

Country Link
US (2) US20040235722A1 (da)
EP (1) EP1399744B1 (da)
JP (1) JP4326326B2 (da)
KR (2) KR100977824B1 (da)
CN (1) CN100406891C (da)
AT (1) ATE397218T1 (da)
AU (1) AU2002317013B2 (da)
CA (1) CA2450502C (da)
DE (1) DE60226867D1 (da)
DK (1) DK1399744T3 (da)
ES (1) ES2307767T3 (da)
HK (1) HK1070694A1 (da)
IL (2) IL158817A0 (da)
NO (1) NO341778B1 (da)
NZ (1) NZ529714A (da)
WO (1) WO2003005036A2 (da)
ZA (1) ZA200309823B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340979A3 (en) * 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
CA2526847C (en) 2003-06-20 2011-01-25 Ambit Biosciences Corporation Assay and kits for detecting protein binding
DK1937723T3 (da) 2005-08-31 2014-02-24 Invion Ltd Modificeret chaperonin 10
CN101514335B (zh) * 2008-02-22 2013-04-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
CN102015757B (zh) * 2008-04-11 2015-12-02 悉生物有限公司 修饰的Cpn10以及PRR信号

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2177179C (en) * 1993-11-30 2006-10-17 Halle Morton Antagonists to chaperonin 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
JP2002502036A (ja) * 1998-02-02 2002-01-22 コンセプト ダイアグノスティクス, インコーポレイテッド 受胎動物を検出する方法および装置
JP2004500039A (ja) * 1999-09-16 2004-01-08 ソルベイ・フアーマシユーチカルズ・ベー・ブイ ヒトg−タンパク質共役型受容体
EP1242448A2 (en) * 1999-11-17 2002-09-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
EP1399744B1 (en) 2008-05-28
WO2003005036A3 (en) 2003-10-16
ATE397218T1 (de) 2008-06-15
IL158817A0 (en) 2004-05-12
ZA200309823B (en) 2005-05-25
ES2307767T3 (es) 2008-12-01
CA2450502A1 (en) 2003-01-16
WO2003005036A2 (en) 2003-01-16
IL158817A (en) 2012-01-31
KR100977824B1 (ko) 2010-08-25
HK1070694A1 (en) 2005-06-24
JP2005503543A (ja) 2005-02-03
US7402563B2 (en) 2008-07-22
CN100406891C (zh) 2008-07-30
CA2450502C (en) 2017-10-31
US20060160145A1 (en) 2006-07-20
DE60226867D1 (de) 2008-07-10
NZ529714A (en) 2008-04-30
US20040235722A1 (en) 2004-11-25
KR20090111346A (ko) 2009-10-26
EP1399744A2 (en) 2004-03-24
JP4326326B2 (ja) 2009-09-02
AU2002317013B2 (en) 2007-11-01
NO341778B1 (no) 2018-01-15
KR100971270B1 (ko) 2010-07-20
NO20035771L (no) 2004-02-26
CN1541335A (zh) 2004-10-27
KR20040010644A (ko) 2004-01-31

Similar Documents

Publication Publication Date Title
Jamil et al. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2
Andersen et al. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules
DK1421389T3 (da) Neurofibrilmarkører
EP1708745A4 (en) ANTIBODIES FOR ONCOGEN STRAINS OF HPV AND METHODS OF USE
JP2006502416A5 (da)
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
Wu et al. Functional proteomics approaches for the identification of transnitrosylase and denitrosylase targets
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
DK0717850T3 (da) Assaykit
Payne et al. A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader
HK1070694A1 (en) Identification of a compound capable of binding to hdrr or capable of modulating hdrr activity using a epf receptor, and isolation of hdrr
EA200200949A1 (ru) Метаболиты агониста/антагониста эстрогена
Amin et al. Correlation between tissue transglutaminase antibodies and endomysium antibodies as diagnostic markers of coeliac disease
SE0000675D0 (sv) Monoclonal antibodies
NO20052870D0 (no) Immunoanalysemetode og sett for anvendelse derav
CA2524002A1 (en) Sars-related proteins
WO2005033330A3 (en) Fluorescent probes for use in protein kinase inhibitor binding assay
DE50011181D1 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
ATE487141T1 (de) Hemmung von gasc1
DE60235011D1 (de) Assays für den präimplantationsfaktor und präimplantationsfaktorpeptide
BR0308095A (pt) Teste para anticorpos anti-ingap
DK1095275T3 (da) Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer
ATE378411T1 (de) Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
WO2006023211A3 (en) Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof